Topics

FDA Grants Fast Track Designation to Triumvira’s TAC01-CD19 for Treatment of Relapsed or Refractory DLBCL

13:37 EST 7 Nov 2019 | Speciality Pharma Journal

AUSTIN, Texas & HAMILTON, Ontario–(BUSINESS WIRE)–Triumvira Immunologics, Inc. (Triumvira), a private, clinical-stage biopharmaceutical company developing a novel platform for engineering T-cells to attack cancers, today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track designation for its novel T-cell therapy product TAC01-CD19 in patients with relapsed or refractory Diffuse Large B-Cell Lymphoma …

Original Article: FDA Grants Fast Track Designation to Triumvira’s TAC01-CD19 for Treatment of Relapsed or Refractory DLBCL

NEXT ARTICLE

More From BioPortfolio on "FDA Grants Fast Track Designation to Triumvira’s TAC01-CD19 for Treatment of Relapsed or Refractory DLBCL"

Quick Search

Relevant Topics

Food
Food is any substance consumed to provide nutritional support for the body. It is usually of plant or animal origin, and contains essential nutrients, such as carbohydrates, fats, proteins, vitamins, or minerals. The substance is ingested by an organism ...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...